12037
document
Fluvoxamine as effective as clomipramine against symptoms of severe depression : results from a multicentre , double-blind study . BACKGROUND Although selective serotonin reuptake inhibitors ( SSRIs ) are better tolerated than tricyclic antidepressants , their efficacy in severe depression remains to be further elucidated . METHOD A double-blind , multicentre study was conducted in 86 severely depressed inpatients ( > or= 25 on the 17-item Hamilton depression rating scale [ HAMD ] total score ) to compare the efficacy and safety of fluvoxamine with that of clomipramine . Following placebo run-in , 86 patients were randomised to receive fluvoxamine or clomipramine ( 100-250 mg/day ) for 8 weeks . RESULTS Fluvoxamine and clomipramine both resulted in marked improvements ; there were no statistically significant differences between them on the 17-item HAMD total score , the clinical global impression severity of illness or global improvement items or the Montgomery-Asberg depression rating scale , at any visit . At the end of the study , 71 % in the fluvoxamine group and 69 % in the clomipramine group were responders ( > or= 50 % decrease in 17-item HAMD total score ) . However , fluvoxamine was better tolerated than clomipramine . Clomipramine was associated with a higher incidence of overall and treatment-related adverse events . In addition , the percentage of patients discontinued prematurely due to adverse events was more than twice as high with clomipramine than with fluvoxamine ( 24 % vs 11 % ) . CONCLUSION Fluvoxamine and clomipramine are equally effective in severe depression , but fluvoxamine has a better safety and tolerability profile .
12038
Intervention_Pharmacological
Fluvoxamine
12039
Intervention_Pharmacological
clomipramine
12040
Intervention_Pharmacological
fluvoxamine
12041
Intervention_Pharmacological
clomipramine .
12042
Intervention_Control
placebo
12043
Intervention_Pharmacological
fluvoxamine or clomipramine
12044
Outcome_Mental
severe depression
12045
Outcome_Other
efficacy
12046
Outcome_Mental
17-item Hamilton depression rating scale [ HAMD ] total score )
12047
Outcome_Other
efficacy
12048
Outcome_Other
safety
12049
Outcome_Other
improvements
12050
Outcome_Mental
17-item HAMD total score
12051
Outcome_Mental
clinical global impression severity of illness
12052
Outcome_Mental
global improvement items or the Montgomery-Asberg depression rating scale
12053
Outcome_Mental
17-item HAMD total score )
12054
Outcome_Other
tolerated
12055
Outcome_Adverse-effects
adverse events
12056
Outcome_Other
discontinued prematurely
12057
Outcome_Adverse-effects
adverse events
12058
Outcome_Other
safety
12059
Outcome_Other
tolerability
12060
Participant_Condition
severe depression
12061
Participant_Sample-size
86
12062
Participant_Condition
depression
12063
Participant_Sample-size
86